Investor Presentation H1 2023
87
Investor presentation
First six months of 2023
Novo NordiskⓇ
In the Explorer 7 trial, concizumab reduced the number of bleeds.
in adults and adolescents with inhibitors
Explorer 7 trial results: Annualised bleeding rate per patient group
Annualised Bleeding Rate (ABR)
100
90
40
40
30
20
20
10
9.8
Median Mean
OnD treatment PPX treatment PPX treatment
0
PPX treatment
HWI
(Group 1)
HWI
(Group 2)
HAWI
(Groups 1-4)
HBWI
(Groups 1-4)
Efficacy
•
Key highlights
Median ABR was 0 for concizumab prophylaxis treatment, compared
to 9.8 in the on-demand treatment group
Estimated mean ABR was 1.7 for concizumab prophylaxis treatment,
compared to 11.8 in the on-demand treatment group
For patients on concizumab prophylaxis, 64% had 0 bleeds in Group 2
Safety
Concizumab appeared to have a safe and well tolerated profile
Status
US Complete Response Letter for HwI received in Q2 2023,
resubmission end of 2023 expected
JP submission for HwI completed in Q3 2022
Explorer8 in non-inhibitor patients was completed in Q3 2022
Primary endpoint
Note: The box represents Q1-Q3 (25th to 75th percentile). Whiskers are 5th and 95th percentile.
HA: Haemophilia A; HB: Haemophilia B; HAWI: Haemophilia A with inhibitors, HBwI: Haemophilia B with inhibitors; HWI: Haemophilia with inhibitors; OnD: On-demand; PPX: Prophylaxis; ABR annualised bleeding rateView entire presentation